MAP2K7 and melanoma: Notably, high expression of EGFR results in a slow-growth phenotype with melanoma cells (Sun et al., 2014), but EGFR turned into a cancer-promoting factor and contributed to the targeted therapy resistance to BRAF or MEK inhibitors (Quadri et al., 2021).